Matching articles for "glargine"
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 14, 2022; (Issue 1663)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
require antihyperglycemic drug therapy. Treating to
a target A1C of <7% while minimizing hypoglycemia
is recommended to prevent microvascular complications
of diabetes (retinopathy, nephropathy, and
neuropathy). An A1C target of <8% may be appropriate
for some older patients.
Tirzepatide (Mounjaro) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • July 11, 2022; (Issue 1654)
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve...
The FDA has approved tirzepatide (Mounjaro –
Lilly), a peptide hormone with activity at both
glucose-dependent insulinotropic polypeptide
(GIP) and glucagon-like peptide-1 (GLP-1)
receptors, to improve glycemic control in adults
with type 2 diabetes. Tirzepatide, which is injected
subcutaneously once weekly, is the first dual GIP/GLP-1 receptor agonist to become available in the
US. Selective GIP receptor agonists are not available
in the US; GLP-1 receptor agonists have been
available for years.
In Brief: Semglee - Insulin Glargine Interchangeable with Lantus
The Medical Letter on Drugs and Therapeutics • October 4, 2021; (Issue 1634)
Insulin glargine-yfgn (Semglee – Viatris), a follow-on
insulin glargine product, has now received
interchangeability status with the reference product
Lantus from the FDA. It is the first biosimilar...
Insulin glargine-yfgn (Semglee – Viatris), a follow-on
insulin glargine product, has now received
interchangeability status with the reference product
Lantus from the FDA. It is the first biosimilar insulin
product to receive this designation in the US. Now a
pharmacist can substitute Semglee for Lantus as a
lower-cost alternative without permission from the
prescriber.
In Brief: Semglee - A New Insulin Glargine for Diabetes
The Medical Letter on Drugs and Therapeutics • January 25, 2021; (Issue 1616)
The FDA has approved Semglee (Mylan), an insulin
glargine product similar to Lantus, for treatment of
type 1 diabetes in children and adults and type 2
diabetes in adults. Semglee is the second...
The FDA has approved Semglee (Mylan), an insulin
glargine product similar to Lantus, for treatment of
type 1 diabetes in children and adults and type 2
diabetes in adults. Semglee is the second "follow-on"
insulin glargine product to become available in
the US; Basaglar, which is also similar to Lantus, was
the first. Lantus is a recombinant analog of human
insulin that forms microprecipitates in subcutaneous
tissue, prolonging its duration of action to a mean of
about 24 hours with no pronounced peak effect.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • November 4, 2019; (Issue 1584)
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of...
Diet, exercise, and weight loss can improve glycemic
control, but almost all patients with type 2 diabetes
eventually require drug therapy. Treating to a glycated
hemoglobin (A1C) concentration of <7% can prevent
microvascular complications (retinopathy, nephropathy,
and neuropathy), but whether it prevents macrovascular
complications and death is unclear. An A1C target of
<8% may be appropriate for older patients and those
with underlying cardiovascular disease (CVD), a history
of severe hypoglycemia, diabetes-related complications,
a limited life expectancy, or a long duration of disease.
Insulins for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 6, 2019; (Issue 1571)
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is...
The goal of drug therapy for type 2 diabetes is to achieve
and maintain a near-normal glycated hemoglobin
(A1C) concentration without inducing hypoglycemia;
for most patients, the target A1C is <7%. Metformin
is the preferred first-line treatment, but most patients
with type 2 diabetes eventually require multidrug
therapy and/or insulin to achieve glycemic control.
Expanded Table: Some Available Insulins for Type 2 Diabetes (online only)
The Medical Letter on Drugs and Therapeutics • May 6, 2019; (Issue 1571)
...
View the Expanded Table: Some Available Insulins
Semaglutide (Ozempic) - Another Injectable GLP-1 Receptor Agonist for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 29, 2018; (Issue 1539)
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the...
The FDA has approved semaglutide (Ozempic – Novo
Nordisk), a long-acting injectable GLP-1 (glucagon-like
peptide-1) receptor agonist, for once-weekly
treatment of adults with type 2 diabetes. It is the sixth
GLP-1 receptor agonist to be approved in the US.
Fiasp - Another Insulin Aspart Formulation for Diabetes
The Medical Letter on Drugs and Therapeutics • January 1, 2018; (Issue 1537)
The FDA has approved Fiasp (Novo Nordisk), a new
formulation of insulin aspart, to improve glycemic
control in adults with diabetes. Fiasp is described by
the manufacturer as faster-acting than...
The FDA has approved Fiasp (Novo Nordisk), a new
formulation of insulin aspart, to improve glycemic
control in adults with diabetes. Fiasp is described by
the manufacturer as faster-acting than conventional
insulin aspart (Novolog).
Insulin Degludec/Liraglutide (Xultophy 100/3.6) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • September 11, 2017; (Issue 1529)
The FDA has approved Xultophy 100/3.6 (Novo
Nordisk), a fixed-ratio combination of insulin
degludec and the GLP-1 (glucagon-like peptide-1)
receptor agonist liraglutide, for once-daily treatment
of adults...
The FDA has approved Xultophy 100/3.6 (Novo
Nordisk), a fixed-ratio combination of insulin
degludec and the GLP-1 (glucagon-like peptide-1)
receptor agonist liraglutide, for once-daily treatment
of adults with type 2 diabetes inadequately controlled
on basal insulin (<50 units daily) or liraglutide (≤1.8
mg daily).
Cardiovascular Effects of Some Antidiabetic Drugs
The Medical Letter on Drugs and Therapeutics • August 14, 2017; (Issue 1527)
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of...
For many years, the goal of drug therapy for most
patients with type 2 diabetes has been to achieve
and maintain an A1C of <7%. Achieving that goal
can prevent microvascular complications (diabetic
retinopathy, nephropathy, neuropathy), but whether it
prevents macrovascular complications (myocardial
infarction [MI], stroke) has been less clear. The FDA
now requires that cardiovascular safety studies be
performed for all new drugs for type 2 diabetes.1
Recent findings that some of the newer second-line
drugs for type 2 diabetes have cardiovascular benefits
have led to new interest in the cardiovascular efficacy
and safety of all antidiabetic drugs.
Prescription Drug Prices in the US
The Medical Letter on Drugs and Therapeutics • May 22, 2017; (Issue 1521)
Per capita spending on prescription drugs in the US is
higher than in other industrialized nations,...
Per capita spending on prescription drugs in the US is
higher than in other industrialized nations, including
Canada.
Lixisenatide for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • January 30, 2017; (Issue 1513)
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide-1)
receptor agonist, for once-daily treatment of adults
with type 2 diabetes, both alone (Adlyxin) and in...
The FDA has approved lixisenatide (Sanofi), a short-acting
injectable GLP-1 (glucagon-like peptide-1)
receptor agonist, for once-daily treatment of adults
with type 2 diabetes, both alone (Adlyxin) and in a
fixed-ratio combination with insulin glargine (Soliqua
100/33). Lixisenatide has been available since 2013 in
many other countries as Lyxumia. It is the fifth GLP-1
receptor agonist to be approved in the US.
Inflectra - An Infliximab Biosimilar
The Medical Letter on Drugs and Therapeutics • January 30, 2017; (Issue 1513)
The FDA has approved infliximab-dyyb (Inflectra –
Pfizer; marketed as Remsima in some countries), as a
biosimilar of the TNF inhibitor infliximab (Remicade).
Infliximab-dyyb was approved in the European...
The FDA has approved infliximab-dyyb (Inflectra –
Pfizer; marketed as Remsima in some countries), as a
biosimilar of the TNF inhibitor infliximab (Remicade).
Infliximab-dyyb was approved in the European Union
(EU) in 2013 and in Canada in 2014. It is the second
biosimilar to be approved by the FDA. Filgastrim-sndz
(Zarxio), a recombinant human granulocyte colony-stimulating
factor, was the first.
Another Insulin Glargine (Basaglar) for Diabetes
The Medical Letter on Drugs and Therapeutics • January 2, 2017; (Issue 1511)
The FDA has approved Basaglar (Lilly/Boehringer
Ingelheim), a "follow-on" 100 units/mL insulin glargine
product similar to Lantus (Sanofi), which recently
went off patent. A 300 units/mL formulation of...
The FDA has approved Basaglar (Lilly/Boehringer
Ingelheim), a "follow-on" 100 units/mL insulin glargine
product similar to Lantus (Sanofi), which recently
went off patent. A 300 units/mL formulation of insulin
glargine (Toujeo) was approved in 2015.
Insulin Degludec (Tresiba) - A New Long-Acting Insulin for Diabetes
The Medical Letter on Drugs and Therapeutics • December 7, 2015; (Issue 1483)
The FDA has approved insulin degludec (Tresiba –
Novo Nordisk) for treatment of adults with type 1 or
type 2 diabetes. Insulin degludec is the third long-acting
human insulin analog to be approved by...
The FDA has approved insulin degludec (Tresiba –
Novo Nordisk) for treatment of adults with type 1 or
type 2 diabetes. Insulin degludec is the third long-acting
human insulin analog to be approved by the
FDA; insulin detemir (Levemir) and insulin glargine
(Lantus, Toujeo) were approved earlier.
Canagliflozin (Invokana) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • May 13, 2013; (Issue 1416)
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2...
Canagliflozin (kan" a gli floe' zin; Invokana – Janssen),
a sodium-glucose co-transporter 2 (SGLT2) inhibitor,
has been approved by the FDA for oral treatment of
type 2 diabetes.
What Comes After Metformin for Type 2 Diabetes?
The Medical Letter on Drugs and Therapeutics • July 23, 2012; (Issue 1395)
Most experts agree that lifestyle modifications and
metformin (Glucophage, and others) should be used
first to treat patients with type 2 diabetes. If metformin
alone fails to control hyperglycemia, there...
Most experts agree that lifestyle modifications and
metformin (Glucophage, and others) should be used
first to treat patients with type 2 diabetes. If metformin
alone fails to control hyperglycemia, there is
no general agreement on which drug should be
added next. A recent article in The Medical Letter
offered some support for a sulfonylurea. Three
recent trials published in The Lancet favored the
long-acting basal insulin glargine, the glucagon-like
peptide (GLP-1) analog exenatide, and the dipeptidyl
peptidase-4 (DPP-4) inhibitor linagliptin, respectively.
Some of the advantages and disadvantages of
these and other available agents are listed in Table 1
on the opposite page.
Insulin Glargine (Lantus) and Cancer Risk
The Medical Letter on Drugs and Therapeutics • August 24, 2009; (Issue 1319)
Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of...
Several large European observational studies published on-line this summer have raised questions about whether use of insulin glargine increases the risk of cancer.
Drugs for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • July 1, 2008; (Issue 71)
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet,...
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, diminished insulin secretion and excess hepatic glucose production. Diet, exercise and weight loss are helpful in improving glucose control, but most patients ultimately require drug therapy.
Insulin Glulisine (Apidra) -- A New Rapid-Acting Insulin
The Medical Letter on Drugs and Therapeutics • April 24, 2006; (Issue 1233)
Insulin glulisine (Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog). All three have a more rapid onset...
Insulin glulisine (Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog). All three have a more rapid onset and shorter duration of action than regular human insulin. Rapid-acting insulin analogs are generally taken immediately before meals and are usually combined with a long-acting basal insulin.
Drugs for Diabetes
The Medical Letter on Drugs and Therapeutics • August 1, 2005; (Issue 36)
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In...
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. In many patients, diet and regular exercise can improve glucose control. Most drugs currently available for management of type 2 diabetes increase insulin supply (sulfonylureas, other secretagogues and insulin itself), decrease insulin resistance (thiazolidinediones) or improve the effectiveness of insulin (biguanides). Alpha-glucosidase inhibitors reduce the rate of glucose absorption. Newer agents such as pramlintide (Symlin) and exenatide (Byetta) have multiple effects to increase satiety and reduce postprandial hyperglycemia.
Drugs for Diabetes
The Medical Letter on Drugs and Therapeutics • September 1, 2002; (Issue 1)
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most...
The development of hyperglycemia in type 2 diabetes results from a combination of metabolic abnormalities including insulin resistance, excess hepatic glucose production and diminished insulin secretion. Most drugs currently available for management of type 2 diabetes fall into 2 categories: those that increase insulin supply (sulfonylureas, other secretagogues and insulin itself) and those that decrease insulin resistance or improve its effectiveness (biguanides, thiazolidinediones). Alpha-glucosidase inhibitors reduce the rate of glucose absorption.